NAN is the home of Trophan and Trophan 2.
The recent report was ALL about Trophan and really scant attention to the Research product pipe line.
UBS initiated coverage with the Heading................".Initiation of CoverageNanosonics LimitedAt an infection point"
There can be little doubt now but that NAN is marketing itself as the INFECTION CONTROL company and Trophan 2 is to be just one of its products.
UBS says ......."however we think endoscope reprocessing and room disinfection arepotential focus areas medium-term"
NAN is the home of Trophan and Trophan 2.The recent report was...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.89 |
Change
0.020(0.52%) |
Mkt cap ! $1.181B | |||
| Open | High | Low | Value | Volume |
| $3.85 | $3.92 | $3.79 | $3.253M | 841.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 136 | $3.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.91 | 5150 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| NAN (ASX) Chart |